ORPHA:398124
Neonatal lupus erythematosus
Publications
2,079
93th percentile
Trials
3
Interventional, condition-specific
Researchers
896
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare systemic autoimmune disease characterized by cutaneous lesions, hepatic dysfunction, hematological abnormalities, and/or cardiac arrhythmia, and caused by transplacental passage of maternal SS-A and SS-B autoantibodies. The most typical cutaneous manifestation is a macular annular erythema affecting the head, but also trunk and extremities. Other reversible features include anemia, neutropenia, thrombocytopenia, and elevation of liver parameters with . The most severe presentation of the disease is irreversible total atrioventricular block.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018360
- MeSH:C536397
- UMLS:C0409979
- NCIT:C99236
Additional Mondo synonyms (1)
Neonatal Lupus
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2,079 matched papers (937 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
3 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
2,079
2,079 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
2,079 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
937 in the last 10 years · high confidence · 93th percentile (publications denominator)
Phrase hits: 2,079 · MeSH hits: 1
Who's working on it?
896
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Zhu X12 papers · 2026
The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Papers in Europe PMC - 02Sun W11 papers · 2026
Department of Neonatology, Children's Hospital of Soochow University, Suzhou, China.
Papers in Europe PMC - 03Li Y8 papers · 2026
Department of Neonatology, Children's Hospital of Soochow University, Suzhou, China.
Papers in Europe PMC - 04Liu X8 papers · 2026
Department of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Papers in Europe PMC - 05Jin X7 papers · 2026
Department of Neonatology, Children's Hospital of Soochow University, Suzhou, China.
Papers in Europe PMC - 06Li L7 papers · 2026
Department of Neonatology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Papers in Europe PMC - 07Wang H7 papers · 2026
Maternal-Fetal Medicine Center in Fetal Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Papers in Europe PMC - 08Fu C5 papers · 2025
Department of Neonatology, Children's Hospital of Soochow University, Suzhou, China.
Papers in Europe PMC - 09Hu J5 papers · 2026
Department of Neonatology, Huai'an Maternal and Child Health Hospital, Huaian, China.
Papers in Europe PMC - 10Huo J4 papers · 2026
Department of Neonatology, Yangzhou Maternal and Child Health Hospital, Yangzhou, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
3
interventional trials for this specific condition
3 interventional trials matched this specific condition name; none in our sample are currently recruiting. 918 trials are registered for lupus erythematosus, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
3 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 85.1th percentile).
high confidence · 85.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
3 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: lupus erythematosus
918
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06711146·RECRUITING·Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
Conditions: Systemic Lupus Erythematosus·Matched via name phrase
- NCT06965244·NOT YET RECRUITING·Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus
Conditions: Cutaneous Lupus Erythematosus (CLE)·Matched via name phrase
- NCT06917742·RECRUITING·A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
Conditions: Healthy Volunteers · Rheumatoid Arthritis · Systemic Lupus Erythematosus·Matched via name phrase
- NCT07318259·RECRUITING·Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
Conditions: Systemic Lupus Erythematosus·Matched via name phrase
- NCT07405970·RECRUITING·A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus·Matched via name phrase
- NCT07201129·RECRUITING·A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Conditions: Nephritis, Lupus · Lupus Erythematosus, Systemic·Matched via name phrase
- NCT06400537·RECRUITING·Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus·Matched via name phrase
- NCT07221565·ENROLLING BY INVITATION·Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
Conditions: Systemic Lupus Erythematosus · Rheumatoid Arthritis · Multiple Sclerosis · Autoimmune Diseases·Matched via name phrase
- NCT04736953·NOT YET RECRUITING·Sirolimus Treatment Of Patients With SLE
Conditions: Lupus Erythematosus, Systemic·Matched via name phrase
- NCT07349667·NOT YET RECRUITING·Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting
Conditions: Arthritis, Juvenile · Arthritis, Juvenile Idiopathic · Lupus Erythematosus, Systemic · Dermatomyositis, Juvenile·Matched via name phrase
- NCT05799378·RECRUITING·Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Conditions: Systemic Lupus Erythematosus·Matched via name phrase
- NCT07038447·ENROLLING BY INVITATION·A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus · Lupus Nephritis · Systemic Sclerosis · Idiopathic Inflammatory Myopathy·Matched via name phrase
- NCT06676631·RECRUITING·NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
Conditions: Refractory Systemic Lupus Erythematosus · Refractory Lupus Nephritis·Matched via name phrase
- NCT07491900·RECRUITING·A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erthematosus (SLE) · Lupus Nephritis (LN) · Extra-renal Lupus (ERL)·Matched via name phrase
- NCT05097365·ENROLLING BY INVITATION·Methyl-donor Nutrient Supplementation and Methylation Profile in Lupus Patients With Obesity
Conditions: Overweight and Obesity · Lupus Erythematosus·Matched via name phrase
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Neonatal lupus erythematosus" OR "Neonatal Lupus"
MeSH descriptor terms unioned into the query: Neonatal Systemic lupus erythematosus
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Neonatal lupus erythematosus" OR "Neonatal Lupus" OR "Neonatal Systemic lupus erythematosus"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 3 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"lupus erythematosus"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:20:40.751Z
